TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05059444: ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Sponsor: Guardant Health, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 2285 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05059444 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05059444 Rescue Dossier →